Amylyx Pharmaceuticals, Inc.
AMLX
Pozycja w akcjach
#4396
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Cena akcji
$28.50
Kapitalizacja rynkowa
$3.58B
Zmiana (1 dzień)
4.26%
Zmiana (1 rok)
85.39%
Kraj
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategoria
Healthcare
Wskaźnik P/B dla Amylyx Pharmaceuticals, Inc. (AMLX)
Wskaźnik P/B na dzień October 2026 TTM: 12.57
Według najnowszych raportów finansowych i ceny akcji Amylyx Pharmaceuticals, Inc., obecny wskaźnik P/B (TTM) wynosi 12.57. Na koniec 2023 wynosił 2.28.
Historia wskaźnika P/B dla Amylyx Pharmaceuticals, Inc. od 2019 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
